Please login to the form below

Not currently logged in
Email:
Password:

Triple negative breast cancer

This page shows the latest Triple negative breast cancer news and features for those working in and with pharma, biotech and healthcare.

Gilead announces positive new data for Trodelvy in metastatic breast cancer

Gilead announces positive new data for Trodelvy in metastatic breast cancer

Trodelvy is currently approved in more than 40 countries for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who have received two or ... help bring Trodelvy to more people living with

Latest news

More from news
Approximately 10 fully matching, plus 82 partially matching documents found.

Latest Intelligence

  • The Age of Diversity, Equality and Inclusion The Age of Diversity, Equality and Inclusion

    Take a trial for triple negative breast cancer, for example, that was done predominantly on white women when it disproportionately affects black women.

  • Patient diversity in clinical trials needs to be centre stage Patient diversity in clinical trials needs to be centre stage

    For example, a few years back we created clinical trial advertising materials for a Triple Negative Breast Cancer study project and, as the condition adversely impacts the black population, we made ... opportunities.”. A blood cancer charity recently

  • Cortellis Drugs to Watch in 2020 report Cortellis Drugs to Watch in 2020 report

    9. Immunomedic’s sacituzumab govitecan initial target market is metastatic triple negative breast cancer in patients who have failed at least two prior therapies. ... It is approved in the US for the treatment of unresectable or metastatic

  • Deal Watch January 2018

    The incoming cash will be used by Immunomedics to fund its operations into 2020 including to progress development of sacituzumab govitecan in metastatic triple-negative breast cancer (TNBC), advanced urothelial cancer ... Tucatinib is currently being

  • Deal Watch February 2017 Deal Watch February 2017

    triple-negative breast cancer (TNBC), small-cell lung cancer (SCLC), non-small-cell lung cancer (NSCLC) and pancreatic cancer. ... Acquisition - company. 2, 475. Immunomedics/ Seattle Genetics. IMMU-132 (sacituzumab govitecan), an antibody drug conjugate

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Origins - The Patient Focused Specialists

Origins creates and delivers patient focused strategy, insights, data and solutions, which guides pharma and biotech companies to improve value...

Latest intelligence

Virtual Steering Committee & Peer Influence Program
In this customer story, we describe the methodology and results of our client’s ongoing Virtual Steering Committee & Peer Influence program....
Meeting healthcare’s rising challenges
The journey to discover novel therapies through digital innovation and ensure scientific advances achieve their potential...
Report gives insights to address gaps in HCP engagement
How does Pharma-HCP engagement need to evolve in today's digital landscape?...